The SAPIEN 3 valve is designed to facilitate future coronary access1

Excellent real-world results for continued coronary access

  • 0.1% (n=1324) coronary obstruction after SAPIEN 3 valve implantation2
  • 100% (68/68) success post-TAVR coronary access 1

Join Edwards Connect

Our exclusive portal grants you access to our latest educational tools, resources, and more to help you communicate with your patients and referrers.

Connect with us

The Edwards SAPIEN platform brochure

When it comes to lifetime management, learn more about how the Edwards SAPIEN 3 platform is designed to deliver a TAVR experience an implanter can count on, starting with the index procedure.

View the brochure

Designed to host future valve reinterventions

Preserving future coronary access is a key consideration in valve-in-valve patients3,4

  • SAPIEN 3 valve-first TAVR reduces risks of future sinus sequestration†5
  • SAPIEN 3 valve-first TAVR facilitates favorable coronary access3

Risk of sinus sequestration if (1) prior TAV commissure level above STJ and (2) the distance between TAV and STJ was <2.0mm in each coronary sinus.

The only platform indicated for both TAV-in-TAV and TAV-in-SAV procedures

Death and Stroke for TAVR with the SAPIEN platform (Native vs Redo)6

Delivering similar outstanding procedural outcomes§ and experience as the index procedure

For patients assessed at high-risk for surgical valve replacement.
§Reported death and stroke.
There are limited data evaluating safety and efficacy of redo-TAVR.

References:   1. Tarantini G, Fovino LN, Le Prince P, et al. Coronary access and percutaneous coronary intervention up to 3 years after transcatheter aortic valve implantation with a balloon-expandable valve. Circ Cardiovasc Interv. 2020;13(7):e008972. 2. Nazif TM, Cahill TJ, Daniels D, et al. Real-world experience with the SAPIEN 3 Ultra transcatheter heart valve: a propensity-matched analysis from the United States. Circ Interventions. 2021; 14:e010543. 3. De Backer O, Landes U, Fuchs A, et al. Coronary access after TAVR-in-TAVR as evaluated by multidetector computed tomography. JACC Cardiovasc Interv. 2020;13(21):2528-2538. doi:10.1016/j.jcin.2020.06.016. 4. Kaneko T, Makkar RR, Krishnaswamy A, et al. Valve-in-surgical-valve with SAPIEN 3 for transcatheter aortic valve replacement based on society of thoracic surgeons predicted risk of mortality. Circ: Cardiovasc Interv. 2021 May;14(5):e010288. 5. Ochiai T, Oakley L, Sekhon N, et al. Risk of coronary obstruction due to sinus sequestration in redo transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2020;13(22):2617-2627. doi:10.1016/j.jcin.2020.09.022. 6. Makkar RR, Kapadia S, Chakravarty T, et al. Outcomes of repeat transcatheter aortic valve replacement with balloon-expandable valves: a registry study. Lancet. Published online August 31, 2023.